[{"id":"67631604-169f-4968-bf77-ff9940ff3dfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04973163","created_at":"2021-07-22T17:52:57.458Z","updated_at":"2024-07-02T16:35:09.277Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation","source_id_and_acronym":"NCT04973163","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 1823911 • BI 1701963 • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-04-17"}]